Urcosimod stable in single-use ampoules for more than 2½ years FDA requires drug to show long-term shelf stability for ...

Randomized 87 patients to date in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED) -- -- ...

On October 22, 2024, we acquired privately-held Opus Genetics Inc., a clinical-stage gene therapy company focused on IRDs, in ...

Vestibular therapy is feasible and may alleviate dizziness symptoms among patients in the emergency department, a pilot study finds.

MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026MZE782 Phase 1 Healthy Volunteer ...

The first clinical trial of a generative AI therapy bot suggests it was as effective as human therapy for people with ...

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the fourth quarter and full-year ended December 31, 2024, and ...

On May 21, 2024, the Company announced that the U.S. Food and Drug Administration (FDA) provided clearance for the Company’s investigational new drug (IND) application to proceed with a Phase 1 ...